GENinCode (LON:GENI) Shares Up 4.1% – Time to Buy?

GENinCode Plc (LON:GENI) rose 4.1% on Tuesday . The stock traded as high as GBX 2.30 and last traded at GBX 2.29. Approximately 517,544 shares traded hands during mid-day trading, a decline of 38% from the average daily volume of 836,486 shares. The stock had previously closed at GBX 2.20.

GENinCode Price Performance

The stock has a market capitalization of £7.17 million, a P/E ratio of -1.06 and a beta of 0.66. The business has a fifty day simple moving average of GBX 2.70 and a 200 day simple moving average of GBX 2.46. The company has a current ratio of 2.60, a quick ratio of 15.89 and a debt-to-equity ratio of 9.28.

GENinCode (LON:GENI) last posted its earnings results on Tuesday, September 30th. The company reported GBX (1.19) earnings per share for the quarter. GENinCode had a negative net margin of 228.70% and a negative return on equity of 289.74%. On average, analysts expect that GENinCode Plc will post -7.1299999 earnings per share for the current year.

GENinCode Company Profile

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.